Eli Lilly and Company (LLY) is gaining notable attention as a preferred pick from experienced investors, namely Billionaire Ken Fisher and Sigma Investments. Though the Alzheimer's drug donanemab was rejected by the European Union due to safety concerns related to brain swelling, it has seen U.S. approval and LillyDirect platform's expansion looks promising in facilitating access to Alzheimer's disease care. Further, LLY is speculated to showcase surprising opportunities in 2025 beyond GLP-1 drugs.
LLY has shown a solid 544% return over the past five years and has successfully expanded its digital platform for Alzheimer's care as well. Looking forward, LLY has received a crucial nod from the U.S. for a GLP-1 pill aimed at obesity treatment and Zepbound vial doses are being launched to cater to self-pay patients.
Interestingly, the company plans to double U.S. manufacturing investment since 2020, exceeding $50 billion and acquired Organovo's FXR Program. Positive signals also come from the stock's steady performance, future innovation potential, and significant long-term returns.
Eli Lilly LLY News Analytics from Thu, 05 Dec 2024 08:00:00 GMT to Sat, 29 Mar 2025 14:16:22 GMT - Rating 4 - Innovation 2 - Information 7 - Rumor -3
